Clayton has been with Freeman Technology since 2008 in a role that has encompassed both sales and applications support. As operations manager he will be responsible for all the day-to-day activities of the company, including overall management of the administration, production, r&d, sales and customer support teams.
In expanding the management team Tim Freeman, director of operations, anticipates further growth and greater opportunity to contribute expertise to the powder processing industries.
‘We want to deliver the best possible technical and applications support to our customers at all times and part of Jamie’s new role will be to ensure that every aspect of our operation runs efficiently,’ he said.
Freeman Technology appoints operations manager
Jamie Clayton takes responsibility for day-to-day activities
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
NICE approval is not enough: why the UK’s next medicines challenge is operational delivery
A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR